Immunomedics, Inc. a clinical-stage biopharmaceutical company based in Morris Plains, NJ (USA) has received U.S. Patent No. 9,107,960 for a new patent family for “Antibody-SN-38 Immunoconjugates with a CL2A Linker.” Expiring in July 2033, the new patent covers improved methods and compositions for preparing, as stated in the patent, “SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments using the CL2A [],” Immunomedics’ proprietary antibody-drug linker.  The patent claims cover the company’s first-in-class antibody-drug conjugates sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are currently being investigated in Phase II trials as a therapy for the treatment of a number of solid tumors and metastatic colorectal cancer, respectively.

As reported recently by the Immunomedics outside clinical investigators during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), both sacituzumab govitecan and labetuzumab govitecan showed encouraging activity with manageable side effects in two separate mid-stage clinical studies in patients heavily-pretreated for their advanced metastatic solid cancers.[2]

“This new patent family adds another layer of critical intellectual property protection for our exciting ADC program in the U.S.,” remarked Cynthia L. Sullivan, President and Chief Executive Officer. “We are committed to advancing sacituzumab govitecan with a corporate partner for the benefit of cancer patients, since it is showing activity in a number of different cancers that have been difficult to treat, especially when they spread,”  Sullivan reiterated.


Advertisement #3 
Advertisement #4